Invuity, Inc. (NASDAQ:IVTY) has earned a consensus recommendation of “Buy” from the seven research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $15.20.
A number of equities analysts have issued reports on the stock. Zacks Investment Research cut shares of Invuity from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Piper Jaffray Companies reissued a “buy” rating and set a $10.00 price target on shares of Invuity in a research report on Wednesday, July 26th. Northland Securities set a $13.00 price target on shares of Invuity and gave the stock a “buy” rating in a research report on Tuesday, June 13th. William Blair reissued a “buy” rating on shares of Invuity in a research report on Tuesday, May 23rd. Finally, Stifel Nicolaus reissued a “buy” rating and set a $10.00 price target (up from $9.00) on shares of Invuity in a research report on Thursday, April 27th.
Shares of Invuity (NASDAQ:IVTY) traded down 0.41% during midday trading on Tuesday, hitting $6.10. The stock had a trading volume of 11,465 shares. The stock’s market cap is $104.01 million. The stock has a 50-day moving average of $7.37 and a 200 day moving average of $7.63. Invuity has a 52 week low of $4.50 and a 52 week high of $14.25.
Invuity (NASDAQ:IVTY) last announced its quarterly earnings data on Tuesday, July 25th. The medical instruments supplier reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by $0.07. Invuity had a negative net margin of 114.61% and a negative return on equity of 140.69%. The business had revenue of $9.77 million during the quarter, compared to the consensus estimate of $10.30 million. Analysts anticipate that Invuity will post ($2.38) EPS for the current fiscal year.
In other news, Director Eric W. Roberts purchased 5,000 shares of Invuity stock in a transaction dated Monday, May 15th. The shares were bought at an average cost of $7.88 per share, with a total value of $39,400.00. Following the completion of the transaction, the director now directly owns 101,529 shares in the company, valued at approximately $800,048.52. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Eric W. Roberts purchased 6,500 shares of Invuity stock in a transaction dated Thursday, May 18th. The shares were purchased at an average cost of $7.07 per share, for a total transaction of $45,955.00. Following the completion of the transaction, the director now owns 106,029 shares of the company’s stock, valued at $749,625.03. The disclosure for this purchase can be found here. Company insiders own 10.50% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Cowen Prime Services LLC boosted its stake in Invuity by 37.3% in the second quarter. Cowen Prime Services LLC now owns 470,050 shares of the medical instruments supplier’s stock valued at $3,408,000 after buying an additional 127,800 shares in the last quarter. Royce & Associates LP boosted its stake in Invuity by 141.9% in the second quarter. Royce & Associates LP now owns 98,939 shares of the medical instruments supplier’s stock valued at $717,000 after buying an additional 58,033 shares in the last quarter. Trexquant Investment LP boosted its stake in Invuity by 119.2% in the second quarter. Trexquant Investment LP now owns 34,580 shares of the medical instruments supplier’s stock valued at $251,000 after buying an additional 18,807 shares in the last quarter. CAPROCK Group Inc. bought a new stake in Invuity during the second quarter valued at approximately $254,000. Finally, Spark Investment Management LLC bought a new stake in Invuity during the second quarter valued at approximately $158,000. 69.58% of the stock is currently owned by institutional investors and hedge funds.
Invuity Company Profile
What are top analysts saying about Invuity Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Invuity Inc. and related companies.